Nucleos(t)ide Analog-Therapeutic Vaccination Switch: A Novel Approach for Safe and Effective Treatment Discontinuation in HBeAg (-) Chronic Hepatitis B Patients.
BACKGROUND/Long-term nucleos(t)ide analog (NUC) therapy effectively suppresses hepatitis B virus (HBV) replication, but it rarely achieves a functional cure and typically requires lifelong administration. NASVAC-based immunotherapy demonstrated durable virological control, a limited but progressive reduction in qHBsAg, and a strong long-term safety profile following the complete withdrawal of antiviral therapy.
BACKGROUND/Long-term nucleos(t)ide analog (NUC) therapy effectively suppresses hepatitis B virus (HBV) replication, but it rarely achieves a functional cure and typically requires lifelong administration. NASVAC-based immunotherapy demonstrated durable virological control, a limited but progressive reduction in qHBsAg, and a strong long-term safety profile following the complete withdrawal of antiviral therapy.
What the study was
- Study design
- Journal article
- Population
- A major unmet need in chronic hepatitis B (CHB) is the development of safe and effective strategies to discontinue NUCs without compromising viral control or hepatic safety.
- Sample size
- 13
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Vaccines
Why it surfaced
Journal article with abstract evidence; scored conservatively for novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.